Merck to Acquire Caraway Therapeutics in a $610 Million Deal

Pharmaceutical giant Merck announced on November 21st that it has reached an agreement to acquire Caraway Therapeutics, a biotechnology company specializing in innovative therapies for neurodegenerative diseases and rare disorders. The deal, valued at $610 million, includes an undisclosed upfront payment and potential milestone payments. This acquisition further strengthens Merck's commitment to advancing treatments for neurodegenerative diseases.

Caraway Therapeutics' Innovative Approach:
Caraway Therapeutics, a preclinical-stage biopharmaceutical company, focuses on developing therapies for neurodegenerative diseases and rare disorders. The company's platform revolves around activating the cell's recycling center, the lysosome, to clear toxic substances and defective cellular components. With an extensive pipeline of products targeting neurodegenerative diseases and rare disorders, Caraway Therapeutics has shown promising progress in evaluating novel mechanisms of lysosome function regulation.

Pipeline and Potential:
Caraway Therapeutics' pipeline currently includes three small molecule drugs in preclinical development for Parkinson's disease, amyotrophic lateral sclerosis (ALS), and lysosomal storage disorders. By leveraging their platform's focus on lysosome function modulation, Caraway Therapeutics has the potential to provide therapeutic options for progressive neurodegenerative diseases.

Merck's Investment and Acquisition Strategy:
Merck initially invested in Caraway Therapeutics through its MRL Ventures Fund in 2018 and has now entered into an agreement to acquire all outstanding shares of the company. This acquisition solidifies Merck's position as a shareholder in Caraway Therapeutics since 2018. Additionally, other investment divisions, such as Amgen and Eisai, have also invested in Caraway Therapeutics, underscoring the promising potential of the company's research and development efforts.

Collaboration with AbbVie and Potential Impact:
In June 2021, Caraway Therapeutics entered into an exclusive collaboration and option agreement with AbbVie to develop and commercialize small molecule therapies targeting TMEM175, a candidate for Parkinson's disease and ALS. With the acquisition by Merck, the development and commercialization collaboration regarding TMEM175 may undergo a transition between Merck and AbbVie.

Merck's Recent Strategic Moves:
Merck's acquisition of Caraway Therapeutics follows its global agreement with Daiichi Sankyo in October 2023, focusing on the application of three DXd-based antibody-drug conjugates in solid tumor indications. This agreement involved an upfront payment of $4 billion to Daiichi Sankyo, with additional milestone payments potentially reaching up to $16.5 billion.

Furthermore, Merck acquired Prometheus Biosciences, an immunology-focused company, for approximately $10.8 billion in June 2023. This acquisition expanded Merck's pipeline with five clinical and preclinical candidates for inflammatory bowel disease and immune-mediated disorders.

Financial Outlook and Growth:
Merck, known for its strong sales of Keytruda, the HPV vaccine Gardasil, and the COVID-19 antiviral drug Lagevrio, reported impressive third-quarter revenue of $15.962 billion in 2023, representing a 7% year-over-year growth. As a result, Merck revised its full-year sales outlook to $59.7 billion to $60.2 billion for 2023.

Merck's acquisition of Caraway Therapeutics underscores its dedication to advancing treatments for neurodegenerative diseases. Leveraging Caraway's innovative approach to lysosome function modulation, Merck aims to develop novel therapies that address the unmet medical needs of patients with neurodegenerative diseases and rare disorders. With its strategic investments and acquisitions, Merck remains committed to driving innovation and delivering transformative healthcare solutions.